The Problem
The Problem
Current standard-of-care options for rheumatoid arthritis leave millions of patients without lasting relief. Remission rates remain low (30–40%), and drug efficacy often diminishes over time—leading nearly half of all patients to discontinue their treatment. Even among those on active therapy, 74% continue to report uncontrolled pain and fatigue. Compounding these efficacy gaps are severe immunosuppressive risks, FDA boxed warnings, high costs, and the inconvenience of injectable biologics. These combined failures drive an urgent need for safer, better-tolerated, and easier-to-administer oral treatments.
Current standard-of-care options for rheumatoid arthritis leave millions of patients without lasting relief. Remission rates remain low (30–40%), and drug efficacy often diminishes over time—leading nearly half of all patients to discontinue their treatment. Even among those on active therapy, 74% continue to report uncontrolled pain and fatigue. Compounding these efficacy gaps are severe immunosuppressive risks, FDA boxed warnings, high costs, and the inconvenience of injectable biologics. These combined failures drive an urgent need for safer, better-tolerated, and easier-to-administer oral treatments.
Bridging the Gap: Addressing the Challenges of Inflammatory Disease Treatment
The challenges of inflammatory disease treatment
The Solution
Radyx was founded to close this therapeutic gap with CG1.4, a plant based polymolecular drug candidate engineered to regulate overactive inflammation across multiple pathways simultaneously. Unlike conventional biologics or DMARDs that broadly suppress the immune system or rely on a single target, CG1.4 is designed to modulate key inflammatory signals like TNF without shutting down essential immune function. Pursued through the FDA Botanical Drug pathway, CG1.4 is intended to leverage this multi pathway approach to offer greater safety, improved tolerance, and convenient oral dosing, with the goal of providing patients lasting relief without severe side effects.
Bridging the gap: addressing the challenges of inflammatory disease treatment
Learn More
Our Team
Freddie Ann Hoffman, MD
CDO
Stephen Morrissey, OMD
CEO/CSO
Staci J Eisner
CoO
Steve R Kishter, MD, DDS
CMO
Richard Samuelson, CFA
CfO
Jenny Morrissey, L.Ac
CHIEF OF STAFF
Freddie Ann Hoffman, MD
CDO
Jolene Anderson
Senior Advisor
Botanical medicine and product development leader with 35+ years of experience.
Former FDA and Pfizer-Warner Lambert development leader.
Quality and regulatory leader in botanical manufacturing.
Clinical and medical development leader in complex therapeutics.
Finance executive and angel investor with multiple company exits.
Co-founder and botanical formulation developer with 30 years of experience.
Investor relations, diligence, and angel network strategist.
CDO
Freddie Ann Hoffman, MD
Freddie Ann Hoffman, MD
Freddie Ann Hoffman, MD
CoO
Staci J Eisner
Staci J Eisner
Senior Advisor
Jolene Anderson
Jolene Anderson
Jolene Anderson
Jolene Anderson
CEO/CSO
Stephen Morrissey, OMD
Stephen Morrissey, OMD
CMO
Steve R Kishter, MD, DDS
Steve R Kishter, MD, DDS
CfO
Richard Samuelson, CFA
Richard Samuelson, CFA
CHIEF OF STAFF
Jenny Morrissey, L.Ac
Jenny Morrissey, L.Ac
Jenny Morrissey, L.Ac.
Our Team
Partners in Innovation
Partners in Innovation
Invest in a company pioneering a new approach to autoimmune disease treatment. Every investment helps bring patients closer to a safer, more effective option than what exists today. Join us at a pivotal moment in that journey.
Invest in a brighter future
Invest in a brighter future
Join us
Join us
